Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMPL Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Impel Pharmaceuticals Stock (NASDAQ:IMPL) 30 days 90 days 365 days Advanced Chart Get Impel Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.04▼$0.8452-Week Range N/AVolume720,000 shsAverage Volume682,655 shsMarket Capitalization$956,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Read More… Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMPL Stock News HeadlinesImpel-Stelda Enters Primary Packaging Business of Tube FillingOctober 12, 2024 | msn.comImexpharm achieves net revenue of US$39.74 million in 2024H1July 26, 2024 | msn.comBig Tech’s $17 Trillion Reckoning DayThe world's biggest tech companies are silently sounding the alarm. While everyday investors keep piling into names like Nvidia, Apple, and Amazon... the owners of those very companies — Jensen Huang, Tim Cook, and Jeff Bezos — are dumping their OWN shares at a record pace. This selling spree is exactly what we saw 25 years ago... right before the dot-com crash wiped out millions of American's portfolios. Now, "America's top trader" is warning that big tech could be barreling right toward another dot-com style implosion.February 10, 2025 | InvestorPlace (Ad)Compliant Marketing In The Pharmaceutical Industry's Regulatory MazeMay 17, 2024 | forbes.comImpel Pharmaceuticals Inc. (IMPLQ)March 13, 2024 | finance.yahoo.comImpel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 ProtectionDecember 20, 2023 | markets.businessinsider.comImpel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate SaleDecember 20, 2023 | finance.yahoo.comAdrian Adams steps down as CEO of Seattle's Impel PharmaceuticalsNovember 6, 2023 | bizjournals.comSee More Headlines IMPL Stock Analysis - Frequently Asked Questions How were Impel Pharmaceuticals' earnings last quarter? Impel Pharmaceuticals Inc. (NASDAQ:IMPL) announced its earnings results on Monday, November, 15th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.42. The company had revenue of $0.09 million for the quarter. When did Impel Pharmaceuticals IPO? Impel Pharmaceuticals (IMPL) raised $80 million in an IPO on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO. What other stocks do shareholders of Impel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Impel Pharmaceuticals investors own include Athenex (ATNX), NIO (NIO), KLX Energy Services (KLXE), American Airlines Group (AAL), Bolt Biotherapeutics (BOLT), Moderna (MRNA) and Novavax (NVAX). Company Calendar Last Earnings11/15/2021Today2/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMPL CUSIPN/A CIK1445499 Webwww.Impelnp.com Phone206-568-1466FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,310,000.00 Net Margins-353.93% Pretax Margin-353.93% Return on EquityN/A Return on Assets-127.43% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.13 Sales & Book Value Annual Sales$20.99 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.86) per share Price / BookN/AMiscellaneous Outstanding Shares23,900,000Free Float22,418,000Market Cap$956,000.00 OptionableNot Optionable Beta1.17 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:IMPL) was last updated on 2/10/2025 by MarketBeat.com Staff From Our PartnersA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrillion-Dollar Wealth Transfer in MotionOne small company is quietly attracting the attention of some of the world's biggest money managers. BlackR...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Secret Winner in Trump’s AI RevolutionTrump just announced a $500 billion plan to revolutionize artificial intelligence. He's calling it The Star...Behind the Markets | SponsoredTop 5 Trump Stocks for His First 100 DaysRight now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredSteve Bannon Sounds Alarm On Elon Musk’s ‘Indefensible Betrayal’Now, if Elon Musk was truly an America First champion… His cronies wouldn't be bragging to the New York Tim...Colonial Metals | SponsoredElon’s ‘Agents’ StrikeHe might be the richest man on the planet – but Elon Musk just landed himself a new job... In a move that c...Altimetry | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Impel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.